Lenalidomide
Lenalidomide is an active ingredient of the class «immunosuppressive drug».
Pair of enantiomers
Boxed warning (US label)
EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Do not use REVLIMID during pregnancy.
What it is used for
- Chronic myelomonocytic leukemia
- Chronic lymphocytic leukemia
- Non-Hodgkin lymphoma
- Central nervous system lymphoma
- Myelofibrosis
- Waldenström macroglobulinemia
- Mature T-cell and NK-cell lymphoma
- Lymphoblastic leukemia
- Mycosis fungoides
- Lymphoma
- Plasmacytoma
- Chromosome 5q deletion syndrome
- Diffuse large B-cell lymphoma
- Acute myeloid leukemia
- Mantle cell lymphoma
- Leukemia
- Multiple myeloma
- B-cell lymphoma
- Anemia
- Refractory anemia with excess blasts in transformation
REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone. • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT). • Transfusion-dependent anemia due to low- or…
Multiple myeloma Revlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
How it works
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
- CRL4(CRBN) E3 ubiquitin ligase modulator
Class: immunosuppressive drug
Common side effects
The following clinically significant adverse reactions are described in detail in other sections of the prescribing information: o Embryo-Fetal Toxicity o Hematologic Toxicity o Venous and Arterial Thromboembolism o Increased Mortality in Patients with CLL o Second Primary Malignancies o Increased Mortality in…
Who should not take it
Pregnancy ( Boxed Warning, 4.1, 5.1, 8.1 ). • Demonstrated severe hypersensitivity to lenalidomide. 4.1 Pregnancy REVLIMID can cause fetal harm when administered to a pregnant female.
Pregnancy and breastfeeding
Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in females exposed to REVLIMID during pregnancy as well as female partners of male patients who are exposed to REVLIMID. This registry is also used to understand the…
Interactions
Brand names
United States
Revlimid
European Union
Lenalidomide Accord · Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) · Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) · Lenalidomide Mylan · Revlimid
Canada
Apo-Lenalidomide · Eugia-Lenalidomide · Jamp Lenalidomide · Nat-Lenalidomide · Reddy-Lenalidomide · Revlimid · Sandoz Lenalidomide · Taro-Lenalidomide
Other trade names
Lenalidomide krka d.d.
Approval status
- US Food and Drug Administration
- prescription · since 2005
- European Medicines Agency
- authorised · since 2007
- Health Canada
- prescription · marketed
- First approval anywhere
- 2005
Codes
- ATC
- L04AX04, L04AX07
- RxNorm CUI
- 342369
- ChEMBL
- CHEMBL848
- PubChem CID
- 216326
- UNII
- F0P408N6V4
- Wikidata
- Q425681
Frequently asked questions
What is Lenalidomide used for?
Lenalidomide is used for: Chronic myelomonocytic leukemia, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Central nervous system lymphoma, Myelofibrosis, Waldenström macroglobulinemia, Mature T-cell and NK-cell lymphoma, and Lymphoblastic leukemia.
What kind of medicine is Lenalidomide?
Lenalidomide is an active ingredient of the class «immunosuppressive drug».
What are the brand names of Lenalidomide?
Brand names of Lenalidomide include Revlimid, Lenalidomide Accord, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Mylan, Apo-Lenalidomide, Eugia-Lenalidomide, and Jamp Lenalidomide.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)